Towards a new combination therapy for tuberculosis with next generation benzothiazinones

The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo-enzyme DprE1, decaprenylphosphoryl-beta-D-ribose 2-epimerase. Here, we synthesized a new series of piperazine-containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Makarov, Vadim, Lechartier, Benoit, Zhang, Ming, Neres, João, Sar, Astrid M, Raadsen, Susanne A, Hartkoorn, Ruben C, Ryabova, Olga B, Vocat, Anthony, Decosterd, Laurent A, Widmer, Nicolas, Buclin, Thierry, Bitter, Wilbert, Andries, Koen, Pojer, Florence, Dyson, Paul J, Cole, Stewart T
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2014
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3958311/
https://ncbi.nlm.nih.gov/pubmed/24500695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/emmm.201303575
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars